US4466917A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Malaria vaccine
Assignee: New York University
•
Filing: 1981-02-12
•
Granted: 1984-08-21
•
Expires: 2001-02-12
Abstract
Abstract The present invention provides antisera and monoclonal antibodies directed against the sporozoite stage of the malaria parasite capable of providing protection against infection in both animals and humans. The invention further provides a purified antigen derived from sporozoites of the malaria parasite, the antigen being suitable for use as a vaccine against malarial infections in both animals and humans. The invention further provides means for preparing said antigen and a vaccine comprising said antigen.
Inventors
- 👤 Ruth S. Nussenzweig
- 👤 G. Nigel Godson
- 👤 Victor Nussenzweig
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:40
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/20; C07K16/205; C07K14/00; C07K14/435; C07K14/44; C07K14/445; A; A61; A61K; A61K39/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/808
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
39 words
An antigenic protein consisting essentially of a sporozoite polypeptide selected from the group consisting of Pb-44, derived from Plasmodium berghei; Pk-44, derived from Plasmodium knowlesi; Pf-44, derived from Plasmodium falciparum; and Pv-44, derived from Plasmodium vivax; in purified form.
Claim 2
Dependent Claim
39 words
An antigenic protein consisting essentially of a sporozoite polypeptide selected from the group consisting of Pb-44, derived from Plasmodium berghei; Pk-44, derived from Plasmodium knowlesi; Pf-44, derived from Plasmodium falciparum; and Pv-44, derived from Plasmodium vivax; in purified form.
Claim 3
Dependent Claim
13 words
The antigenic protein of claim 1, consisting essentially of Pb-44 in purified form.
Claim 4
Dependent Claim
13 words
The antigenic protein of claim 1, consisting essentially of Pk-44 in purified form.
Claim 5
Dependent Claim
13 words
The antigenic protein of claim 1, consisting essentially of Pf-44 in purified form.
Claim 6
Dependent Claim
13 words
The antigenic protein of claim 1, consisting essentially of Pv-44 in purified form.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-21 | 1988-02-20 | 1988-08-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-21 | 1992-02-20 | 1992-08-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-21 | 1996-02-20 | 1996-08-21 | $7700.00 | Window Closed / Lapsed |